GEMS (Genesis Exploration of Molecular Space) is a generative AI platform for small-molecule drug discovery.
GEMS integrates deep-learning generative models, physics-based molecular simulation, and large-scale compute to predict molecular properties and generate novel chemical matter.
The platform supports internal and partnered drug-discovery programs by enabling the exploration of challenging, data-poor, and previously undruggable targets.
Atomic AI
ATOM-1
atomic.ai
Enveda Biosciences
Enveda Drug Discovery Platform
enveda.com
1910
ITO Platform
1910genetics.com
Origin Bio
Origin Bio — Cancer Biology Platform
origin.bio
Insilico Medicine
Pharma.ai
insilico.com
Recursion Pharmaceuticals
Recursion OS
recursion.com
| Attribute | GEMS AI Platform | ATOM-1 | Enveda Drug Discovery Platform | ITO Platform | Origin Bio — Cancer Biology Platform | Pharma.ai | Recursion OS | |
|---|---|---|---|---|---|---|---|---|
| Provider |  | | | | | | | |
| Founded | 2019 | 2021 | 2019 | 2018 | 2025 | 2014 | 2013 | |
| Sells To | Enterprise | Enterprise | Enterprise | Enterprise | B2B, Pharmaceutical Manufacturers | Enterprise | Enterprise | |
| Pricing Model | Recurring, Software | Recurring | Recurring | Recurring, Software | B2B, Licensing | Recurring, Software | Recurring, Software | |
| Ownership | Venture Capital | Venture Capital | Venture Capital | Private Equity, Venture Capital | Private | Venture Capital | Public, Venture Capital |
Provider
Founded 2019
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture Capital
Provider
Founded 2021
Sells To Enterprise
Pricing Model Recurring
Ownership Venture Capital
Provider
Founded 2019
Sells To Enterprise
Pricing Model Recurring
Ownership Venture Capital
Provider
Founded 2018
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private Equity, Venture Capital
Provider
Founded 2025
Sells To B2B, Pharmaceutical Manufacturers
Pricing Model B2B, Licensing
Ownership Private
Makya
iktos.ai
